Speaker

Pete is Vice President of Cancer Biology at Revolution Medicines where he has been a scientific leader on programs with diverse targets and modalities, including allosteric SHP2 inhibitors, bi-steric mTORC1-selective inhibitors, and RAS(ON) tri-complex inhibitors. Previously he led the Biochemistry Department and industrial protein engineering projects at DuPont Industrial Biosciences. Pete received an AB in Biology from Cornell University and a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley under Dr. Susan Marqusee, and was a post-doctoral fellow in Dr. Jim Wells’s group at the University of California, San Francisco.

« Go Back